Premium
Serum antibodies to GM1 and GM3‐gangliosides in systemic lupus erythematosus with chronic inflammatory demyelinating polyradiculoneuropathy
Author(s) -
Sindern E.,
Stark E.,
Haas J.,
Steck A. J.
Publication year - 1991
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1991.tb03971.x
Subject(s) - medicine , polyradiculoneuropathy , autoantibody , chronic inflammatory demyelinating polyneuropathy , pathogenesis , polyneuropathy , ganglioside , immunology , systemic lupus erythematosus , lupus erythematosus , pathology , sural nerve , antibody , guillain barre syndrome , disease , biochemistry , chemistry
Acute symmetric demyelinating polyneuropathy of the Guillain‐Barré type is known in systemic lupus erythematosus (SLE). Chronic idiopathic demyelinating polyneuropathy (CIDP) has been reported rarely with SLE. A case is reported of CIDP accompaning SLE with autoantibodies against GM1‐and GM3‐gangliosides. There was no historical evidence to suggest SLE, and CIDP was the first manifestation of SLE. The 38‐year‐old patient had elevated CSF‐protein, slow nerve conduction velocities, sural nerve biopsy revealed mixed axon loss with demyelination and CIDP white matter lesions were observed in magnetic resonance imaging. the GM1‐and GM3‐autoantibodies may play a role in the pathogenesis of CIDP in SLE.